Literature DB >> 19660876

Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus.

Sinisa M Trbovic1.   

Abstract

Psychosis and dreaming have many similarities, including delusions, hallucinations, bizarre thinking and perceptual distortions. This clinical observation has lead us to hypothesize that the suprachiasmatic nucleus (SCN), a hypothalamic center regulating sleep and wakefulness, is involved in the pathogenesis of schizophrenia. Schizophrenic patients have certain sleep architecture characteristics, and distinctive biological markers suggesting abnormity of the SCN, including irregular pattern of melatonin secretion, abnormal actigraphyic studies, D1-dopamine receptors involvement in the process of entraining the SCN and vulnerability to psychotic exacerbation due to jet lag. In addition, SCN lesions in rodents are associated with pathologic day-time sleep pattern, very similar to the sleeping pattern in patients with schizophrenia. We introduce the concept of REM sleep abnormity as a possible etiological factor in development of psychosis. We hypothesize that the proposed dysfunction of the SCN may contribute to schizophrenia through several different, not necessarily mutually exclusive, mechanisms, including "REM sleep (dream) rebound" phenomenon, damaged neuronal pathways connecting SCN to the brain regions affected by schizophrenia, and the SCN dysfunction induced dysregulation of gene expression in different parts of the body, including the brain. Moreover, the influenza virus, which has been implicated in the etiology of schizophrenia, is capable of resetting the SCN, the ultimate processor of light signals, suggesting the explanation for chronological variability of incidence of schizophrenia. Future investigation of the proposed mechanisms will provide the ultimate test of our hypothesis that lesions of the suprachiasmatic nucleus play an important role in the etiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660876     DOI: 10.1016/j.mehy.2009.07.019

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

Review 1.  Jet lag and psychotic disorders.

Authors:  Gregory Katz
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

2.  Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.

Authors:  Hans-Gert Bernstein; Susan Müller; Hendrik Dobrowolny; Carmen Wolke; Uwe Lendeckel; Alicja Bukowska; Gerburg Keilhoff; Axel Becker; Kurt Trübner; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-29       Impact factor: 5.270

3.  Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.

Authors:  Hae Jeong Park; Jin Kyung Park; Su Kang Kim; Ah-Rang Cho; Jong Woo Kim; Sung-Vin Yim; Joo-Ho Chung
Journal:  J Mol Neurosci       Date:  2011-04-28       Impact factor: 3.444

Review 4.  Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.

Authors:  Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-05       Impact factor: 5.270

Review 5.  Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review.

Authors:  Konstantinos Assimakopoulos; Katerina Karaivazoglou; Maria Skokou; Marina Kalogeropoulou; Panagiotis Kolios; Philippos Gourzis; George P Patrinos; Evangelia Eirini Tsermpini
Journal:  Medicines (Basel)       Date:  2018-03-24

6.  Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review.

Authors:  Rébecca Robillard; Naomi L Rogers; Bradley G Whitwell; Tim Lambert
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-04-30       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.